Lion Point Capital, LP is an SEC-registered investment adviser based in New York, NY that reports managing 2 hedge funds on Form ADV. It reports $480.6 million in regulatory assets under management. Its private funds, of all types, hold $480.5 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +14.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +90.4% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $480.6 millionForm ADV Item 5.F
- Gross assets of private funds
- $480.5 millionAll private fund types, Form ADV
- Hedge funds managed
- 25 private funds in total
- Employees
- 7Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 174322
- Latest Form ADV
- 04/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +22.2% | +14.8% |
| Q1 2026 | -6.1% | -4.6% |
| Q4 2025 | +19.8% | +2.4% |
| Q3 2025 | +39.7% | +7.8% |
| Q2 2025 | +8.8% | +10.4% |
| Q1 2025 | -15.8% | -4.5% |
| Q4 2024 | +3.9% | +2.1% |
| Q3 2024 | +4.1% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 34 share positions ($17,261,149) reported by Lion Point Capital, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Cue Biopharma Inc7.93%
- Praxis Precision Medicines I7.51%
- Royalty Pharma PLC7.24%
- Fennec Pharmaceuticals Inc6.94%
- Compass Pathways PLC5.77%
- Moonlake Immunotherapeutics4.58%
- Geron Corp4.12%
- Milestone Pharmaceuticals In4.11%
- Biohaven LTD4.00%
- Syndax Pharmaceuticals Inc3.92%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Cue Biopharma Inc | $1,369,247 | 7.93% | 52,928 | Unchanged |
| Praxis Precision Medicines I | $1,295,974 | 7.51% | 4,450 | Unchanged |
| Royalty Pharma PLC | $1,248,904 | 7.24% | 21,400 | Unchanged |
| Fennec Pharmaceuticals Inc | $1,197,422 | 6.94% | 112,434 | Unchanged |
| Compass Pathways PLC | $995,200 | 5.77% | 80,000 | Unchanged |
| Moonlake Immunotherapeutics | $789,750 | 4.58% | 67,500 | Unchanged |
| Geron Corp | $710,940 | 4.12% | 578,000 | Unchanged |
| Milestone Pharmaceuticals In | $709,874 | 4.11% | 820,000 | Unchanged |
| Biohaven LTD | $690,195 | 4.00% | 51,700 | Unchanged |
| Syndax Pharmaceuticals Inc | $676,800 | 3.92% | 36,000 | Unchanged |
| Benitec Biopharma Inc | $620,000 | 3.59% | 62,000 | Unchanged |
| Disc Medicine Inc | $530,226 | 3.07% | 8,100 | Unchanged |
| Sarepta Therapeutics Inc | $519,270 | 3.01% | 28,500 | Unchanged |
| Kura Oncology Inc | $492,660 | 2.85% | 46,000 | Unchanged |
| Viatris Inc | $490,844 | 2.84% | 27,700 | Unchanged |
| Ardelyx Inc | $439,983 | 2.55% | 128,650 | Unchanged |
| Edgewise Therapeutics Inc | $369,460 | 2.14% | 9,100 | Unchanged |
| Uniqure NV | $355,152 | 2.06% | 14,700 | Unchanged |
| Azenta Inc | $338,433 | 1.96% | 9,700 | Unchanged |
| Pacira Biosciences Inc | $338,175 | 1.96% | 13,500 | Unchanged |
| Humacyte Inc | $336,505 | 1.95% | 650,000 | Unchanged |
| Bridgebio Pharma Inc | $329,000 | 1.91% | 5,000 | Unchanged |
| Janux Therapeutics Inc | $328,320 | 1.90% | 19,000 | Unchanged |
| Dyne Therapeutics Inc | $289,980 | 1.68% | 18,000 | Unchanged |
| Jasper Therapeutics Inc | $269,700 | 1.56% | 465,000 | Unchanged |
| Mineralys Therapeutics Inc | $263,865 | 1.53% | 10,500 | Unchanged |
| GH Research PLC | $239,496 | 1.39% | 10,200 | Unchanged |
| Rocket Pharmaceuticals Inc | $226,180 | 1.31% | 86,000 | Unchanged |
| Regenxbio Inc | $200,298 | 1.16% | 26,600 | Unchanged |
| Innoviva Inc | $173,922 | 1.01% | 8,200 | Unchanged |
| Arcutis Biotherapeutics Inc | $138,758 | 0.80% | 5,250 | Unchanged |
| Innate Pharma S A | $132,276 | 0.77% | 81,151 | Unchanged |
| Seres Therapeutics Inc | $105,760 | 0.61% | 31,570 | Unchanged |
| Spruce Biosciences Inc | $48,580 | 0.28% | 1,000 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 0 new positions, 1 sold out, 0 increased, 0 reduced and 34 unchanged.
Number of positions (a count, not dollars)
- New positions0
- Increased0
- Unchanged34
- Reduced0
- Sold out1
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Lantheus Hldgs Inc | $610,170 | 5,500 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Oct 8, 2024. Funds also listed from Form D are shown above.
Fund vehicles: feeder funds and single-deal vehicles (1)
Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures